The REVIVE Pivotal Study
NCT: NCT07361653 · NOT_YET_RECRUITING
Brief Summary
The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD). The main questions it aims to answer are: 1. Does the TLD Catheter improve symptoms in people with COPD? 2. Is the TLD Catheter safe ? Researchers will compare the group receiving the TLD treatment to the group receiving a sham procedure to see if the treatment improves quality of life. Participants will: 1. Be randomly assigned to receive either the TLD treatment or a sham procedure. 2. Undergo the assigned procedure in a hospital setting. 3. Attend follow-up visits for health checks and breathing tests.
Frequently Asked Questions
What is The REVIVE Pivotal Study?
The REVIVE Pivotal Study is a clinical trial registered under NCT07361653. Current status: NOT_YET_RECRUITING.
What is the status of NCT07361653?
The current status of NCT07361653 (The REVIVE Pivotal Study) is: NOT_YET_RECRUITING.
When did The REVIVE Pivotal Study start?
The REVIVE Pivotal Study started on 2026-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.